76 results about "Tissue fibrosis" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to application of oxibenzophenone in preparation of a medicine for treating pathological cardiac hypertrophy and / or heart failure. Research results in myocardial cells of primary newborn rats show that Exibenzophenone can inhibit pathological hypertrophy of myocardial cells induced by phenylephrine (PE). Animal experiments show that the epoxybenzophenone can improve cardiac dysfunction induced by aortic arch constriction (TAC) and reduce cardiac hypertrophy and cardiac tissue fibrosis. The invention provides a new drug research and development approach and a drug action target for treating pathological cardiac hypertrophy and heart failure, and has very important medicinal value.

Provided are a recombinant human interleukin-11 mutant, and a conjugate of the mutant conjugated to a chemical molecule and a use thereof. The recombinant human interleukin-11 mutant achieves soluble expression in an Escherichia coli expression system by means of an SUMO sequence tandem fusion method. The conjugate is obtained by the site-specific conjugation of the mutant to the chemical molecule at a mutant amino acid residue in position W147 by means of a covalent bond. The chemical molecule is at least one of polyethylene glycol, an alkanoic acid aliphatic chain, and a hydrophilic high-molecular polymer containing an alkanoic acid aliphatic chain. The conjugate retains the binding capacity to human interleukin-11 receptor A while demonstrating significantly reduced binding capacity to human IL-6 signal transducer receptor. The conjugate shows the ability to block the signaling between human IL-11 and IL-11 RA and between human IL-11 and GP130 either in vivo or in vitro and can be used for the treatment of associated diseases with tissue fibrosis as a clinical manifestation caused by elevated primary or secondary IL-11.

The invention discloses a biological medicine application of luwulinine, and provides and verifies that luwulinine can inhibit disulfiram death of cells for the first time, so that luwulinine can be used for preventing or treating hepatic ischemia reperfusion injury. Experimental data show that the luteiniine can relieve liver function injury after reperfusion with cell apoptosis, tissue inflammation infiltration and tissue fibrosis as manifestations, and a new direction is provided for mechanism research and prevention and treatment of hepatic ischemia reperfusion injury.

This invention relates to the field of traditional Chinese medicine and natural medicines, and discloses a traditional Chinese medicine composition for treating thyroiditis, nodular goiter, and thyroid nodules, as well as its preparation method and application. The traditional Chinese medicine composition is made from raw materials in parts by weight of 1-30 parts of Prunella vulgaris, 1-30 parts of Taraxacum mongolicum, 1-30 parts of Hordeum vulgare malt, 1-20 parts of Citrus reticulata peel, 1-24 parts of Crataegus pinnatifida, and 1-24 parts of Raphanus sativus seed. It can not only significantly reduce serum TgAb and TPOAb antibody levels, inhibiting the attack of autoimmune response on the thyroid gland from the source, but also effectively reduce lymphocyte infiltration, repair damaged thyroid follicular structure and restore colloid content, thereby reversing immune damage and tissue destruction of the thyroid gland, reducing thyroid nodules, and solving the problems of existing treatments for thyroiditis, nodular goiter, and thyroid nodules that cannot reverse immune damage to the thyroid gland, destruction of follicular structure, and tissue fibrosis.

The present invention discloses the use of CTRP13 in the preparation of a drug for treating renal fibrosis. Experimental studies have shown that CTRP13 inhibits Smad3, inhibiting renal tubular epithelial cell transdifferentiation, thereby preventing and / or treating renal fibrosis. Furthermore, CTRP13 lacks the common hepatotoxicity and renal cytotoxicity seen with other renal fibrosis inhibitors, thus demonstrating its safety. This suggests that CTRP13 could be widely used as a drug for treating renal fibrosis caused by infections, drugs, aging, hypertension, and other conditions.

The invention belongs to the technical field of biological medicines, and particularly relates to application of MIM2 and derivatives thereof in preparation of products for treating tissue fibrosis. It is found that the compound MIM2 can effectively inhibit expression and synthesis of various cancers (extracellular matrix proteins such as collagen and laminin in cells). In-vitro experiments show that after MIM2 treatment, collagen and laminin expression of the cancer cells, skin fibroblasts, hepatic stellate cells and embryonic lung cells is remarkably reduced. Animal experiments further prove that the MIM2 can effectively inhibit collagen deposition in tumor tissues of tumor-bearing mice, can slow down the fibrosis process of liver fibrosis and pulmonary fibrosis mouse models, and can reduce the level of plasma hyaluronic acid at the same time. The results show that the MIM2 has the effects of inhibiting extracellular matrix deposition and delaying tissue fibrosis, and is expected to be developed into small molecular drugs for treating cancer-related fibrosis and other fibrosis diseases.

The integrin family of cell adhesion molecules has emerged as key mediators of tissue fibrosis. A pharmacological inhibitor of multiple integrin subtypes is required to produce meaningful effects on delaying or inhibiting the progression of fibrosis. Monoclonal antibodies recognizing multiple integrins with potent neutralizing activity and having human and mouse cross-reactivity are described. In particular, monoclonal antibodies that bind human αvβ1, αvβ3, αvβ5, αvβ36, αvβ38, and α5β1 integrins and mouse αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8 integrins are described.

The application discloses application of a novel peptide UHP in preparation of a medicine for treating and / or preventing delayed aging, and belongs to the technical field of biological medicines.The novel peptide UHP is composed of 37 L-type amino acids including a transmembrane peptide HIV-TAT.It is proved by cell experiments that the novel peptide UHP significantly improves the aging phenotype of a HGPS cell model simulated by overexpression of progerin and a replicative senescent human normal fibroblast cell, reduces the SA-beta-gal positive cell proportion and the expression of SASP factors, and increases the expression levels of cell proliferation markers Ki67, Lamin B1 and Cyclin A2.It is proved by animal experiments that the novel peptide UHP can improve the progeria phenotype, body weight and exercise capacity of a progeria mouse, relieve fibrosis in multiple tissues, improve the skin aging phenotype, and prolong the survival period of the progeria mouse, thereby providing a new medicine selection for clinical treatment of aging-related diseases.

To provide a novel TGF-β signal transduction inhibitor.SOLUTION: An extract of Oenothera biennis L. is used as an active ingredient. The extract of Oenothera biennis L. has a TGF-β signal transduction inhibitory effect and thus suppresses TGF-β-induced promotion of fibrosis in tissues. Therefore, it can be expected to have preventive and therapeutic effects on fibrotic diseases, and preventive and improving effects on cellulite.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of biomedicine, and particularly discloses an endowed mesenchymal stem cell, an endowed mesenchymal stem cell composition and application of the endowed mesenchymal stem cell composition to preparation of a medicine for treating organ insufficiency, and the endowed mesenchymal stem cell is obtained by treating human mesenchymal stem cells with ingenol HEP14. The energizing mesenchymal stem cell composition comprises energizing mesenchymal stem cells and HEP14 / PLGA microspheres which are prepared by adopting a polylactic acid-glycolic acid copolymer (PLGA) as a carrier and have high HEP14 loading capacity and long-acting HEP14 slow release. The energized mesenchymal stem cell has the effects of enhancing the survival activity and dryness of the mesenchymal stem cell, resisting tissue fibrosis, promoting tissue angiogenesis, and promoting tissue regeneration and functional recovery; the endowed mesenchymal stem cells and the HEP14 / PLGA microspheres are used in a combined manner, and the retention and transdifferentiation effects of the endowed mesenchymal stem cells in tissues are enhanced, so that the functions of the endowed mesenchymal stem cells and the application of the endowed mesenchymal stem cells in the field of regenerative medicine are further enhanced.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

The present invention includes a method of treating fibrosis in a human patient in need thereof comprising administering to the human patient in need of treatment a therapeutically effective amount of Prolactin-Inducible Protein (PIP) which is capable of inhibiting or reversing the formation of pathogenic fibrils, e g., fibrosis that affects at least one organ selected from the group consisting of skin, intestine, heart, liver, lung, and kidney.

This invention relates to a formulation and method of application of a multicomponent mycotoxin detoxifier for poultry feed, particularly female broiler chickens, which aims to provide protection to the Bursa Fabricius due to exposure to mycotoxins in the form of aflatoxin and ochratoxin. The mycotoxin detoxifier formulation according to this invention consists of an inorganic mycotoxin binder in the form of bentonite and / or zeolite, an organic mycotoxin binder in the form of pectin and / or esterified cellulose, and a natural antioxidant in the form of vitamin E and / or antioxidant herbal extracts. The formulation is applied to poultry feed at a dose of 2 to 2.5 g per kg of feed and is able to bind aflatoxin and ochratoxin simultaneously in the digestive tract, thereby reducing the bioavailability of mycotoxins.The application of this formulation has been proven to reduce histopathological damage to the Bursa of Fabricius, including lymphoid follicle depletion, cyst formation, cell necrosis, inflammatory cell infiltration, and tissue fibrosis, while also supporting the immune system function of female broiler chickens. This invention provides an effective, efficient, and easily applicable technical solution in the poultry farming industry to address mixed mycotoxin contamination in feed.

The invention relates to an application of a succinate dehydrogenase subunit SDHC protein and a coding gene thereof in preparation of a medicine for preventing and / or treating renal fibrosis, and belongs to the field of biological medicines. The invention proposes and verifies that SDHC gene delivery can alleviate kidney pathological changes of chronic kidney diseases for the first time; the expression level of kidney tissue fibrosis related indexes is reduced; the transdifferentiation of renal tubular epithelial cells to myofibroblasts is inhibited. SDHC gene delivery can achieve the effect of improving the chronic kidney disease, and good development and application prospects are achieved.

The present disclosure provides a composition for treating or preventing fibrosis and / or inflammation in an organ or tissue in a subject. The present disclosure specifically provides a composition for treating or preventing fibrosis and / or inflammation in an organ or tissue in a subject, the composition containing macrophages derived from monocytes stimulated with IL-34. The composition can be produced by a method comprising: a step for preparing a sample comprising CD14-positive cells; an optional step for isolating the CD14-positive cells from the sample if required; and a step for bringing the sample or the isolated CD14-positive cells into contact with IL-34.

This disclosure generally relates to the use of (24S)-3β-hydroxy-5α-stigmastan-6-one in the preparation of a medicament for the treatment of benign prostatic hyperplasia, inflammation or fibrosis, and the medicament being administered to individuals in need of treatment at a dose of 0.1-50 mg / kg body weight.

The invention belongs to the field of biological medicine, and particularly relates to application of a compound YS434 in preparation of medicine for preventing and / or treating pulmonary fibrosis and a medicine composition of the compound YS434. The small molecule compound YS434 can treat pulmonary fibrosis by reducing collagenous fiber deposition, relieving inflammatory response, promoting alveolar epithelial tissue repair and inhibiting the pulmonary tissue fibrosis process, provides a new choice for the medicine for clinically treating pulmonary fibrosis, and has a good application prospect.

The invention relates to the technical field of biological medicines, in particular to application of wild buckwheat rhizome freeze-dried powder in preparation of a medicine for preventing or treating antimony pneumoconiosis. A mouse antimony pneumoconiosis model is constructed by injecting an antimony (Sb) suspension into a trachea, and pulmonary fibrosis lesion caused by antimony exposure can be remarkably relieved by intragastric administration of the wild buckwheat rhizome freeze-dried powder prepared by the invention. Experimental results show that Hamp; e dyeing indicates that the freeze-dried powder can obviously relieve the fibrosis severity of the lung tissue; western Blot and PCR (Polymerase Chain Reaction) detection results show that the wild buckwheat rhizome can partially inhibit the expression up-regulation of Col-1 and alpha-SMA induced by antimony in protein and gene levels; in addition, the wild buckwheat rhizome can also obviously reduce the content of hydroxyproline in lung tissues. The results show that the wild buckwheat rhizome freeze-dried powder can effectively improve multiple pathological indexes and reduce the pulmonary fibrosis degree, has good potential in the aspect of preventing antimony pneumoconiosis, and has potential application value.

The invention relates to the technical field of immunotherapy, in particular to a method for preparing CAR-M and / or CAR-T with enhanced cell killing ability. The method comprises the steps that CAR-M and / or CAR-T are / is cultured on hydrogel, so that the CAR-M and / or CAR-T with the enhanced cell killing capacity are / is obtained, the hydrogel is gelatin-oxidized sodium alginate cross-linked hydrogel, and the oxidation degree is 50%; the material has the energy storage modulus of 1953 to 1120Pa, the loss modulus of 112.0 to 42.81 Pa, the loss coefficient of 0.06945 to 0.03730 and the stress relaxation coefficient of 2915 to 2019s. The CAR-M cell therapy is introduced into pulmonary fibrosis treatment for the first time, and hydrogel with optimal parameters is combined, so that the treatment efficiency of CAR-M / CAR-T cells is improved, the killing ability is improved by at least four times, and pulmonary tissue fibrosis is effectively relieved.

The present application provides methods for treating or preventing diseases and conditions associated with tissue fibrosis.

The application provides a traditional Chinese medicine external application method for reducing the risk of fistula fibrosis in dialysis patients, relates to the technical field of clinical application of traditional Chinese medicine, is suitable for the prevention of autologous arteriovenous fistula fibrosis of maintenance hemodialysis patients, can effectively reduce the incidence of complications such as fistula peripheral tissue fibrosis and vascular stenosis, and prolongs the service life of the fistula. The drug stability and skin permeability are improved through optimization of adjuvants, and based on the grouping intervention of maintenance hemodialysis patients, the fistula blood flow and fibrosis improvement are evaluated in combination with color Doppler ultrasound. The application takes the principles of promoting blood circulation to remove blood stasis, dredging collaterals and resolving knots, and detoxification and swelling reduction as the therapeutic principles, prepares a fistula protection ointment by screening and optimizing a traditional Chinese medicine formula, realizes the effects of improving local microcirculation of the fistula, inhibiting fibrous tissue proliferation and reducing inflammatory reactions through external application intervention, thereby reducing the incidence of fistula fibrosis and related complications, prolonging the fistula patency time, simultaneously reducing the treatment cost, and improving the patient tolerance and life quality.

The application of a class of N-substituted phenyl-2-pyridone compounds in treating cancer and relieving fibrosis belongs to the technical field of medicine. The compound is an N-substituted phenyl-2-pyridone compound or a pharmaceutical derivative or preparation thereof. The cancer includes one or more of common cancers such as lung cancer, breast cancer, liver cancer, prostate cancer, pancreatic cancer and the like. The fibrosis disease includes one or more of diseases such as pulmonary fibrosis, liver fibrosis, kidney fibrosis, myocardial fibrosis and the like or diseases induced by fibrosis. The drug can be combined with one or more pharmaceutical carriers to form a drug combination. The drug or the pharmaceutical composition thereof can be used alone or in combination with other drugs. The class of N-substituted phenyl-2-pyridone compounds has anticancer efficacy and presents excellent ability to relieve organ and tissue fibrosis, has good safety, and is expected to be developed into a clinical first-line drug.

Methods of treating tissue fibrosis and / or injury and / or organ failure using an interleukin 24 (IL-24) protein or an interleukin 20 (IL-20) antagonist are provided.

The invention discloses photoresponsive protein hydrogel with wide-area mechanical regulation characteristics. The photoresponsive protein hydrogel is formed by polymerizing a specific mutant of photoactivated xanthoprotein (PYP) and a multi-arm polyethylene glycol derivative with the tail end modified with a maleimide group. Through rational design of molecular dynamics and material mechanics, cysteine mutation is carried out on the 48th site and the 85th site of a wild type PYP sequence, and the PYP (48 / 85) double mutant with an anisotropic unfolding energy scene is constructed. According to the mutant, exposed sulfydryl and a multi-arm polyethylene glycol derivative are subjected to Michael addition reaction to form a cross-linked network. Compared with the prior art (such as PYP 36 / 128 hydrogel), the method has the advantages that higher mechanical sensitivity and unfolding probability of PYP 48 / 85 under network tension are utilized, the limitation that traditional design only depends on chain length change is overcome, and remarkably larger macroscopic rigidity adjusting amplitude (the mechanical switch ratio can reach 70% or above) is achieved. The material has the characteristics of good biocompatibility, high response speed (millisecond level), complete reversibility and wide rigidity dynamic range, and can meet the biological application requirements of stem cell differentiation, tissue fibrosis model construction and the like with high requirements on a mechanical signal threshold.

This invention discloses a method for constructing a PBMC-derived humanized mouse scleroderma model. Human peripheral blood mononuclear cells are transplanted into immunodeficient mice, and a human immune system is reconstructed in the mice. Bleomycin is injected into the local skin of the mice in a round-point manner to induce fibrosis and form a scleroderma model. This application can more comprehensively simulate the complex pathological process of immune abnormalities and tissue fibrosis coexisting in human scleroderma, and provides a more realistic and systematic experimental platform for in-depth exploration of the immune mechanism of this disease.

The invention provides application of 4-hydroxyphenylpyruvic acid or 4-hydroxyphenylacetic acid in preparation of a medicine for preventing and / or treating metabolism-related fatty liver fibrosis, and belongs to the field of biological medicine. The invention provides new application of 4-hydroxyphenylpyruvic acid and 4-hydroxyphenylacetic acid. The 4-hydroxyphenylpyruvic acid and the 4-hydroxyphenylacetic acid can be used for preparing medicines for preventing and / or treating metabolism-related fatty liver fibrosis. Specifically, 4-hydroxyphenylpyruvic acid or 4-hydroxyphenylacetic acid is independently administered to inhibit activation of hepatic stellate cells and improve mouse hepatic tissue fibrosis and liver function impairment caused by CDAHFD diet. The 4-hydroxyphenylpyruvic acid and the 4-hydroxyphenylacetic acid are tyrosine metabolites derived from endogenous organisms and / or intestinal flora, and have no obvious toxicity to organisms; the invention provides a more effective and innovative prevention and treatment method for clinical treatment of metabolism-related fatty liver fibrosis, and has important clinical value.

The present invention relates to an autoantigen-specific nanofusion vaccine composition for the treatment of systemic sclerosis, the composition being for simultaneous immunomodulation and antifibrosis. A nanofusion body carrying a vimentin peptide according to the present invention was found to inhibit tissue fibrosis in systemic sclerosis, reduce the amount of autoantibodies in serum, and regulate the expression of immune-regulatory cells and pathogenic cells associated with systemic sclerosis. The nanofusion body was also found to inhibit tissue fibrosis and to exhibit enhanced anti-fibrotic effects, when co-administered with a vimentin antibody, in an animal model reflecting the immune status of systemic sclerosis patients. In addition, the nano-vaccine was found to decrease the expression of fibrotic and pathogenic factors in tissues and was also found to improve disease activity not only in vimentin-specific systemic sclerosis but also in infection-associated systemic sclerosis.

The invention belongs to the field of new application of medicines, and particularly relates to application of pimozide in preparation of medicines for treating renal fibrosis diseases. It is found for the first time that pimozide inhibits renal fiber activity by combining with EIF4A1 protein, pimozide can be used as a potential anti-renal fibrosis drug, and a new thought is provided for research of anti-organ or tissue fibrosis drugs.

The utility model relates to the technical field of operating forceps, and discloses a rat nucleus pulposus reoccurrence / recurrence prevention model operating forceps which comprises an operating forceps body, the outer side of the operating forceps body is fixedly connected with two temperature sensors, the outer side of the operating forceps body is fixedly connected with a heat insulation assembly, and the heat insulation assembly is fixedly connected with the operating forceps body. A mounting box is fixedly connected to the outer side of the operating forceps body, a clamping box is fixedly connected to the inner side of the mounting box, an elastic assembly is fixedly connected to the inner side of the clamping box, and a clamping assembly is fixedly connected to the outer side of the elastic assembly; an electric heating piece making contact with the outer side of the operating forceps body is clamped to the inner side of the mounting box through a clamping assembly. The rat nucleus pulposus reoccurrence / recurrence prevention model operating forceps have the advantages that the heating function is achieved, the temperature can be accurately controlled in the operation process, and tissue fibrosis and repair are helped.

The present invention discloses a method for detecting tissue fibrosis, comprising the following steps: (1) capturing a sample to be detected with a bare gold electrode pretreated with a gelatin solution; (2) adding an anti-α-SMA primary antibody to react with the α-SMA in the sample to be detected captured in step (1); (3) adding a secondary antibody against the primary antibody to react with the primary antibody bound to the cells to be detected, the secondary antibody having a biotin label; (4) adding streptavidin to react with the biotin on the secondary antibody bound to the primary antibody; (5) adding tetrahedral DNA nanomaterial and dichlorotris(1,10-o-phenanthroline)ruthenium(II) hydrate to react, and then performing ECL detection to obtain an α-SMA expression signal, thereby detecting the degree of tissue fibrosis. The present invention can directly detect the expression of α-SMA in tissue cells without destroying tissue and cell structure, without the need for homogenizing cells and tissues.